У нас вы можете посмотреть бесплатно Lymphoma Expert | Dr. Kieron Dunleavy on the importance of lymphoma research или скачать в максимальном доступном качестве, которое было загружено на ютуб. Для скачивания выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса savevideohd.ru
World-renowned lymphoma expert Dr. Kieron Dunleavy emphasizes the importance of lymphoma research. Dr. Dunleavy, a Lymphoma Research Foundation's Scientific Advisory Board member, spoke about the importance of funding research to help those affected by this terrible disease and underscored how it could ultimately improve patient outcomes. He highlighted the progress made in understanding lymphoma, from diagnosis to treatment, and expressed his gratitude that patients have been able to benefit from recent research. He also discussed why funding is necessary for furthering our knowledge of this disease. "Lymphoma is, it's about the fifth most common type of cancer. It's a very treatable cancer. I can't tell you how much it's changed over the last ten years because of research. There really has been huge progress. I see this on a daily basis with my patients and often telling them, look, if you were here, five years ago, ten years ago or fifteen years ago, we wouldn't be having this kind of conversation that we're going to cure you. You're going to live now for 30 years because of research and because of partnering with companies, etc...So it's really, really hugely important. And I just can't emphasize that enough." The funds raised will help support vital lymphoma research and allow researchers like Dr. Dunleavy to continue leading the charge against this deadly disease. We are excited to continue partnering with the Lymphoma Research Foundation and working alongside lymphoma experts like Dr. Dunleavy to achieve our mission to improve treatment outcomes for lymphoma patients and increase diversity in cancer research.